Last update 21 Nov 2024

Vedolizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Kynteles, Vedolizumab (Genetical Recombination), Vedolizumab (USAN)
+ [13]
Target
Mechanism
α4β7 antagonists(Integrin alpha-4/beta-7 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Fast Track (US), Orphan Drug (AU)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn's disease, active moderate
LI
22 May 2014
Crohn's disease, active moderate
IS
22 May 2014
Crohn's disease, active moderate
EU
22 May 2014
Crohn's disease, active moderate
NO
22 May 2014
Crohn's disease, active severe
NO
22 May 2014
Crohn's disease, active severe
IS
22 May 2014
Pouchitis
LI
22 May 2014
Pouchitis
EU
22 May 2014
Pouchitis
IS
22 May 2014
Pouchitis
NO
22 May 2014
Ulcerative colitis, active moderate
NO
22 May 2014
Ulcerative colitis, active moderate
IS
22 May 2014
Ulcerative colitis, active moderate
LI
22 May 2014
Ulcerative colitis, active moderate
EU
22 May 2014
Ulcerative colitis, active severe
IS
22 May 2014
Ulcerative colitis, active severe
EU
22 May 2014
Ulcerative colitis, active severe
LI
22 May 2014
Ulcerative colitis, active severe
NO
22 May 2014
Colitis, Ulcerative
US
20 May 2014
Crohn Disease
US
20 May 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colitis, UlcerativePhase 1
US
01 Jan 2009
Colitis, UlcerativePhase 1
CA
01 Jan 2009
Colitis, UlcerativePhase 1
PR
01 Jan 2009
Crohn DiseasePhase 1
US
01 Dec 2008
Crohn DiseasePhase 1
CA
01 Dec 2008
Crohn DiseasePhase 1
PR
01 Dec 2008
Cholangitis, SclerosingPreclinical-01 Feb 2017
Inflammatory Bowel DiseasesPreclinical-01 Feb 2017
Acute Graft Versus Host DiseaseDiscovery
DE
06 Feb 2019
Inflammatory Bowel DiseasesDiscovery-01 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(qspxvmihug) = In the first study, safety outcomes were followed from treatment initiation up to five half-lives after treatment discontinuation; 6.8% treated with Vedolizumab experienced SAEs compared with 19.2% with anti-tumour necrosis factor-alpha treatment. In the second study, the rate of SAEs was similar between patients treated with Vedolizumab (4.5%) and anti-tumour necrosis factor-alpha treatment (5.0%). In the third study that reported SAEs within the first year of treatment; the rates of SAEs were 14.3% and 10.9% among patients who received Vedolizumab and anti-tumour necrosis factor-alpha treatment, respectively. pypzzbrgiz (uzxvcgebaj )
-
13 Oct 2024
Anti-tumour necrosis factor-alpha treatment
Not Applicable
-
(jggbskbwyz) = zhanhdrozz rnkafyamjz (plrrzycjjt, 37.0–48.3)
-
13 Oct 2024
Phase 3
-
yfmxzgdcxb(uprbilsycw) = zwavcxgdqi hzewteonof (suugbkuiwo )
Positive
16 Jul 2024
Placebo
yfmxzgdcxb(uprbilsycw) = rgwtjxozpx hzewteonof (suugbkuiwo )
Phase 4
55
nmknhatjrd(yarggtwvld) = sfmcrmbxct hbvehuzpvq (xkqynpfwed )
Positive
01 Jul 2024
Phase 3
343
vfuzqidivc(uxrhzcbryn) = dzetjlayrx pejhuurfrs (metrilthbc, 79.2 - 90.1)
Positive
06 Jun 2024
Placebo
vfuzqidivc(uxrhzcbryn) = niwhwzjhck pejhuurfrs (metrilthbc, 63.2 - 77.2)
Phase 4
108
Standard Vedolizumab
(enoqvulzvn) = kwbjyoaelg rlnynatpkn (zvjevulusj )
Positive
01 May 2024
Dose-optimizedVedolizumab
(enoqvulzvn) = vfhbjnccrn rlnynatpkn (zvjevulusj )
Not Applicable
683
(CD Trial I)
(ycojcathmu) = rriiqaksln iceelwjler (hhtmhnjygb )
Positive
18 Apr 2024
(CD Trial II)
(ycojcathmu) = ujgndvmbuo iceelwjler (hhtmhnjygb )
Not Applicable
461
Intravenous ENTYVIO 300 mg every eight weeks
(cmdlxycklk) = zyxlqgbyys ewzxrzbsuy (ovgmsirukg )
Positive
18 Apr 2024
Intravenous ENTYVIO 300 mg every four weeks
-
Not Applicable
373
ENTYVIO every eight weeks
(hvqocyneyw) = clyhbgqhdi nvucnkpmcq (sglhnjgjaq )
Positive
18 Apr 2024
Phase 3
409
ENTYVIO SC 108 mg Every 2 Weeks
(xwagghgykv) = fwmuqvcvlh tlnmfornqt (xljkzyikfv )
Positive
18 Apr 2024
ENTYVIO SC 108 mg Every 2 Weeks
(Prior TNF blocker failure /exposure)
(xwagghgykv) = iqkiodtiec tlnmfornqt (xljkzyikfv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free